TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line.
A novel human myeloma cell line, OH-2, was established from pleural fluid of a myeloma patient in end stage of the disease. Effects of cytokines on proliferation were analyzed by measuring uptake of 3H-thymidine. Cell surface antigens were detected by flow cytometry. The cell line is dependent on IL-6 for growth and proliferates in response to TNF. There is synergy between the stimulatory response of TNF and IL-6. The cells express both the p55 and p75 TNF receptors. Neutralizing anti-IL-6 did not inhibit TNF-mediated proliferation, showing that TNF acts through a pathway that is independent of IL-6. TNF was more potent than IL-6 in stimulating the growth of primary myeloma cultures (> 99% pure) from the same patient (OH-2-PC), indicating that TNF in selected myeloma patients has a growth-promoting effect equal to IL-6. OH-2 cells produce and secrete monoclonal IgG-kappa.
Börset
M
M
Institute of Cancer Research, University of Trondheim, Norway.
Waage
A
A
Brekke
O L
OL
Helseth
E
E
D015703:Antigens, CD / Q000032:analysis; D002455:Cell Division; D002467:Cell Nucleus / Q000473:pathology; D004247:DNA / Q000032:analysis / Q000096:biosynthesis; D004721:Endoplasmic Reticulum / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D006056:Golgi Apparatus / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007145:Immunoglobulin kappa-Chains / Q000378:metabolism; D016130:Immunophenotyping; D015850:Interleukin-6 / Q000494:pharmacology*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000473:pathology*; D010996:Pleural Effusion / Q000473:pathology; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D015703:Antigens, CD; D007074:Immunoglobulin G; D007145:Immunoglobulin kappa-Chains; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D004247:DNA